Adult Leukemia Research Center

成人白血病研究中心项目 该项目的总体目标是改善异基因造血细胞移植（HCT） 作为血液恶性肿瘤的治疗。具体而言，我们建议进行实验室和临床研究， 提高移植的安全性，增强移植的抗肿瘤作用，拓宽移植的靶点， 移植的可用性，并提高我们在适当的时候应用移植的能力， 病程。提出了六个单独的项目： 1.非清髓性造血细胞同种异体移植 2.移植物抗宿主病的免疫遗传学 3.移植物抗宿主病的防治 4.慢性粒细胞白血病的耐药与复发 5.白血病的特异性免疫治疗 6.靶向同种异体反应性治疗白血病 此外，还要求在生物统计学、病理学、微生物学和病毒学、胃肠病学、 肺内科和肾脏病学、细胞处理、长期随访和给药。的能力 成功地开展拟议的工作是非常有益的：（1）存在一个庞大的群体， 研究者都专注于HCT的一般主题;（2）我们中心强大的临床前研究计划 支持这一主题;（3）每年增加450-500名移植患者参加研究方案。 与公共卫生的相关性：该计划项目与18，000多名患者直接相关 每年接受同种异体HCT治疗造血系统恶性肿瘤的患者。工作提出的 承诺使移植更安全，更有效，更容易获得，更合适 应用。此外，从我们计划的研究中吸取的教训将适用于移植耐受性问题， 恶性疾病进展的分子基础，特别是癌症的免疫治疗。

Adult Leukemia Research Center Program Project The overall goal of this program project is to improve allogeneic hematopoietic cell transplantation (HCT) as treatment for hematological malignancies. Specifically, we propose laboratory and clinical studies to increase the safety of transplantation, to enhance the anti-tumor effects of transplantation, to broaden the availability of transplantation, and to improve our ability to apply transplantation at the appropriate time in the course of disease. Six individual projects are proposed: 1. Nonmyeloablative Hematopoietic Cell Allotransplants 2. Immunogenetics of Graft-Versus-Host Disease 3. Prevention and Treatment of Graft-Versus-Host Disease 4. Resistance and Relapse of Chronic Myeloid Leukemia 5. Specific Adoptive Immunotherapy of Leukemia 6. Targeting Alloreactivity for Leukemia Eradication In addition, core support is requested in biostatistics, pathology, microbiology and virology, gastroenterology, pulmonary medicine and nephrology, cell processing, long-term follow-up, and administration. Our ability to successfully carry out the proposed work is greatly benefited by: (1) the existence of a large group of investigators all focused on the general topic of HCT; (2) strong preclinical research programs at our Center in support of this topic; and (3) the accrual of 450-500 transplant patients onto research protocols each year. Relevance to Public Health: This Program Project has direct relevance to the more than 18,000 patients who undergo allogeneic HCT for treatment of hematopoietic malignancies each year. The work proposed promises to make transplantation safer, more effective, increasingly available and more appropriately applied. Further, lessons learned from our planned studies will apply to issues of transplant tolerance, the molecular basis of malignant disease progression, and especially the immunotherapy of cancer.